Myelodysplastic syndromes/neoplasms (MDSs) encompass a range of hematopoietic malignancies, commonly affecting elderly individuals. Molecular alterations in the hematopoietic stem cell compartment drive disease pathogenesis. Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.
骨髓增生异常综合征/肿瘤（MDSs）是一类造血系统恶性肿瘤，常见于老年人群。造血干细胞区室的分子改变驱动疾病的发生发展。基因组分析技术的最新进展为理解MDSs的生物学基础提供了重要见解，并拓展了治疗选择，尤其针对特定分子定义亚组。本综述重点阐述其诊断原则、分类更新、预后分层系统及新型治疗方法，这些进展可为未来临床试验提供参考，并改善成人MDS患者的管理策略，特别是针对特定分子定义亚组。
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms
肿瘤(癌症)患者之家